GlycoT Therapeutics Grants Sublicense of Glycoengineering Technology to Daiichi Sankyo
BALTIMORE, Sept. 14, 2020 /PRNewswire/ -- GlycoT Therapeutics LLC, a UM Ventures start-up company based on intellectual property (IP) developed at the University of Maryland, Baltimore (UMB) and University of Maryland, College Park (UMCP), has executed a sublicense agreement for its glycoengineering technology with Daiichi Sankyo Company, Limited (Daiichi Sankyo; www.daiichisankyo.com). The agreement grants Daiichi Sankyo worldwide and non-exclusive rights to IP that GlycoT currently licenses from UMB and UMCP, and includes an undisclosed upfront payment, annual fees, and adequate royalties of sales to GlycoT.
GlycoT's enzymatic glycoengineering technology provides a platform to precisely change and modify the sugars on antibodies. Daiichi Sankyo plans to use this cutting-edge technology to prepare new drug candidates.
"We are very excited to see the growing potential for GlycoT's glycoengineering technology," said Phil Robilotto, DO, MBA, associate vice president of UMB's Office of Technology Transfer and director of UM Ventures, which is UMB and UMCP's joint technology transfer initiative. "This is a great example of how university innovators continue to fuel therapeutic development across the globe."
Lai-Xi Wang, PhD, Founder and President of GlycoT Therapeutics and UMCP Professor in the Department of Chemistry and Biochemistry, developed the technologies that are the basis for the GlycoT/Daiichi Sankyo license agreement in his lab, first at UMB and later at UMCP.
"We are pleased to provide the opportunity for Daiichi Sankyo to use this technology," said Dr. Wang. "We believe our technology has the potential to open new avenues for developing novel therapeutics for the treatment of human diseases."
About GlycoT Therapeutics LLC
About UM Ventures
SOURCE University of Maryland Ventures